

Craig B Reeder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5821320/publications.pdf>

Version: 2024-02-01

71
papers

1,864
citations

361413

20
h-index

265206

42
g-index

71
all docs

71
docs citations

71
times ranked

2422
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e89-e95.	0.4	2
2	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 308-315.	1.3	3
3	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 355-360.	0.4	5
4	Assessment of fixed-duration therapies for treatment of Waldenstrom macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	4.1	12
5	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	3.0	32
6	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 1639-1639.	1.4	3
7	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021, 138, 1750-1750.	1.4	2
8	"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma- the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021, 11, 196.	6.2	28
9	A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2020, 136, 2401-2409.	1.4	92
10	"Direct to Drug" screening as a precision medicine tool in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 54.	6.2	20
11	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	2.4	81
12	Syngotropic and folliculotropic mycosis fungoides with mycosis fungoides-associated vasculopathic ulcers. <i>JAAD Case Reports</i> , 2019, 5, 231-233.	0.8	4
13	The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672). <i>Blood</i> , 2019, 134, 1591-1591.	1.4	3
14	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. <i>Blood</i> , 2019, 134, 2774-2774.	1.4	0
15	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , 2019, 134, 1904-1904.	1.4	0
16	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	1.8	71
17	A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2128-2134.	1.3	5
18	Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma. <i>JAMA Oncology</i> , 2018, 4, 859.	7.1	1

#	ARTICLE	IF	CITATIONS
19	Necrobiotic xanthogranuloma: a 30-year single-center experience. <i>Annals of Hematology</i> , 2018, 97, 1471-1479.	1.8	33
20	Ibrutinib-induced acute liver failure. <i>Leukemia and Lymphoma</i> , 2018, 59, 512-514.	1.3	8
21	<i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	4.1	57
22	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 70.	6.2	18
23	Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2018, 93, 1220-1226.	4.1	9
24	Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 486-492.e1.	0.4	7
25	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 622-622.	1.4	1
26	Depth of Response in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 4141-4141.	1.4	2
27	Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). <i>Blood</i> , 2018, 132, 4138-4138.	1.4	0
28	Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. <i>American Journal of Hematology</i> , 2017, 92, 759-763.	4.1	25
29	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	3.0	115
30	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	7.1	110
31	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	2.5	25
32	Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, 642.	6.2	15
33	Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. <i>Blood</i> , 2016, 128, 2415-2422.	1.4	51
34	Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, E504-E505.	4.1	6
35	Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study. <i>Blood</i> , 2016, 128, 1786-1786.	1.4	6
36	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	1.4	2
38	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. Blood, 2016, 128, 1810-1810.	1.4	0
39	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study. Blood, 2016, 128, 5322-5322.	1.4	0
40	Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients. Blood, 2016, 128, 3452-3452.	1.4	0
41	Treatment of Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2015, 90, 1054-1081.	3.0	106
42	Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. Bone Marrow Transplantation, 2014, 49, 201-205.	2.4	20
43	<sc>AT</sc>â€101 downregulates <sc>BCL</sc>2 and <sc>MCL</sc>1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and <sc>W</sc>aldenström macroglobulinaemia. British Journal of Haematology, 2014, 164, 352-365.	2.5	30
44	Longätterm survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. British Journal of Haematology, 2014, 167, 563-565.	2.5	41
45	Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood, 2014, 124, 1047-1055.	1.4	185
46	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clinic Proceedings, 2013, 88, 360-376.	3.0	440
47	Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment.. Journal of Clinical Oncology, 2013, 31, 8514-8514.	1.6	4
48	A Phase I/II Combination Of RAD001 (Everolimus) and Lenalidomide For Relapsed Lymphoid Malignancy: Phase I Results. Blood, 2013, 122, 4350-4350.	1.4	0
49	Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs. Blood, 2013, 122, 1928-1928.	1.4	0
50	Impact Of Vitamin D Level Pre and Post Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2013, 122, 4616-4616.	1.4	2
51	The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087) Tj ETQq1 1 0.784314 ogBT /Over	1.4	0
52	Reduced Toxicity Conditioning With Fludarabine, BCNU, Melphalan and Anti-Thymocyte Globulin Followed By Allogeneic Stem Cell Transplant For Patients With Primary and Post ET/PV Myelofibrosis: Single Center Experience At Mayo Clinic Arizona. Blood, 2013, 122, 2835-2835.	1.4	0
53	New diagnosis of multiple myeloma in a patient with mantle cell lymphoma: Shared genetic factors or simple coincidence?. Leukemia Research Reports, 2012, 1, 7-8.	0.4	1
54	Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML): Low Incidence of Relapse and Graft Versus Host Disease (GVHD) in Patients (pts) Transplanted without Active Leukemia Using in-Vivo T-Cell Depletion with Rabbit Anti-Thymocyte Globulin (r-ATG). Blood, 2011, 118, 4527-4527.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies.. Blood, 2010, 116, 2799-2799.	1.4	2
56	A Phase I/II Trial of Lenalidomide and RCHOP (R2CHOP) in Patients with Newly Diagnosed Diffuse Large B-Cell (DLBCL) and Follicular Grade 3 Lymphoma.. Blood, 2009, 114, 1669-1669.	1.4	7
57	Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).. Blood, 2009, 114, 1676-1676.	1.4	7
58	A Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone (RCD) in Patients with Light Chain Amyloidosis.. Blood, 2009, 114, 3853-3853.	1.4	8
59	Pomalidomide (CC4047) Plus Low Dose Dexamethasone (Pom/dex) Is Active and Well Tolerated in Lenalidomide Refractory Multiple Myeloma (MM).. Blood, 2009, 114, 429-429.	1.4	4
60	Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003). Journal of Clinical Oncology, 2009, 27, e19504-e19504.	1.6	1
61	Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Who Had Received Prior Stem Cell Transplant.. Blood, 2009, 114, 2699-2699.	1.4	8
62	Kinome-Wide RNAi Studies in Human Multiple Myeloma Identify a Lymphoid Restricted Kinase GRK6 as a Selectively Vulnerable Target That Regulates STAT3/MCL1.. Blood, 2009, 114, 601-601.	1.4	0
63	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.. Blood, 2009, 114, 587-587.	1.4	2
64	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).. Blood, 2007, 110, 121-121.	1.4	31
65	mTOR Inhibition for Relapsed or Refractory Hodgkin Lymphoma: Promising Single Agent Activity with Everolimus (RAD001).. Blood, 2007, 110, 2555-2555.	1.4	14
66	A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls.. Blood, 2007, 110, 3601-3601.	1.4	4
67	Kinetin Riboside Is a Novel Targeted Inhibitor of CCND1 and CCND2 Transactivation with Substantial Preclinical Anti-Myeloma Activity.. Blood, 2006, 108, 367-367.	1.4	0
68	Chemical Library Screening Identifies Novel Inhibitors of Cyclin D2 (CCND2) Transactivation That Selectively Induce Apoptosis in Multiple Myeloma Cells.. Blood, 2006, 108, 3421-3421.	1.4	0
69	Hepatic B-cell non-Hodgkin's lymphoma of MALT type in the liver explant of a patient with chronic hepatitis C infection. Liver Transplantation, 2005, 11, 796-799.	2.4	20
70	A Phase I Trial of Oblimersen Sodium (G3139) for Relapsed or Refractory Waldenstrom Macroglobulinemia.. Blood, 2004, 104, 2407-2407.	1.4	0
71	Trimolecular Complexes of λ Light Chain Dimers in Serum of a Patient with Multiple Myeloma. Clinical Chemistry, 2002, 48, 1805-1811.	3.2	69